| Datum |
Zeit |
Quelle |
Überschrift |
|---|
| 29.4.2024 | 13:57 | GLOBE | ZyVersa Therapeutics Announces Publication Reinforcing the.. |
| 04.4.2024 | 13:57 | GLOBE | ZyVersa Therapeutics Highlights Published Data Demonstrating.. |
| 25.3.2024 | 13:17 | GLOBE | ZyVersa Therapeutics Reports Full Year 2023 Financial.. |
| 18.3.2024 | 12:57 | GLOBE | ZyVersa Therapeutics Announces IRB Approval of Phase 2a.. |
| 14.3.2024 | 12:57 | GLOBE | ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate.. |
| 08.3.2024 | 23:00 | EDGAR2 | Form 8-K - Current report |
| 08.3.2024 | 23:00 | EDGAR2 | Form PRE 14A - Other preliminary proxy statements |
| 29.2.2024 | 13:57 | GLOBE | ZyVersa Therapeutics Generated Approximately $2.7 Million.. |
| 28.2.2024 | 13:57 | GLOBE | ZyVersa Therapeutics Highlights Data from Review Article.. |
| 22.2.2024 | 13:47 | GLOBE | ZyVersa Therapeutics Publishes New White Paper Detailing the.. |
| 14.2.2024 | 22:34 | EDGAR2 | Form S-8 - Securities to be offered to employees in employee.. |
| 14.2.2024 | 13:53 | GLOBE | ZyVersa Therapeutics Highlights Review Article.. |
| 07.2.2024 | 14:02 | GLOBE | ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at.. |
| 31.1.2024 | 13:57 | GLOBE | ZyVersa Therapeutics Highlights Publication Indicating That.. |
| 24.1.2024 | 13:57 | GLOBE | ZyVersa Therapeutics Announces Peer-Reviewed Article.. |
| 19.1.2024 | 12:19 | EDGAR2 | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 17.1.2024 | 13:52 | GLOBE | ZyVersa Therapeutics Highlights Peer-Reviewed Article.. |
| 10.1.2024 | 14:06 | GLOBE | ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on.. |
| 04.1.2024 | 13:50 | GLOBE | ZyVersa Therapeutics Announces Equity Research Coverage.. |
| 03.1.2024 | 14:07 | GLOBE | ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter.. |
| 22.12.2023 | 22:45 | EDGAR2 | Form 8-K - Current report |
| 18.12.2023 | 14:12 | GLOBE | ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate.. |
| 14.12.2023 | 13:01 | GLOBE | ZyVersa Therapeutics Engages CRO, George Clinical, for Phase.. |
| 11.12.2023 | 22:30 | EDGAR2 | Form 8-K - Current report |
| 08.12.2023 | 22:44 | EDGAR2 | Form 424B4 - Prospectus [Rule 424(b)(4)] |
| 07.12.2023 | 17:20 | GLOBE | ZyVersa Therapeutics Announces Publication Demonstrating.. |
| 07.12.2023 | 06:15 | EDGAR2 | Form EFFECT - Notice of Effectiveness |
| 07.12.2023 | 03:00 | GLOBE | ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million.. |
| 06.12.2023 | 13:20 | GLOBE | ZyVersa Therapeutics Announces Publication Showing AIM2 and.. |
| 30.11.2023 | 17:45 | EDGAR2 | Form 8-K - Current report |
| 30.11.2023 | 17:30 | GLOBE | ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and.. |
| 20.11.2023 | 23:15 | EDGAR2 | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 17.11.2023 | 22:15 | EDGAR2 | Form 8-K - Current report |
| 14.11.2023 | 22:35 | GLOBE | ZyVersa Therapeutics Reports Third Quarter 2023 Corporate.. |
| 09.11.2023 | 13:35 | GLOBE | ZyVersa Therapeutics Announces Article Published in.. |
| 06.11.2023 | 13:05 | GLOBE | ZyVersa Therapeutics Announces Article in Peer-Reviewed.. |
| 02.11.2023 | 21:37 | EDGAR2 | Form 8-K - Current report |
| 01.11.2023 | 13:07 | GLOBE | ZyVersa Therapeutics Announces Publication in Molecular.. |
| 25.10.2023 | 12:50 | GLOBE | ZyVersa Therapeutics Announces Research Published in the.. |
| 24.10.2023 | 22:15 | EDGAR2 | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 18.10.2023 | 13:05 | GLOBE | ZyVersa Therapeutics Announces a Publication in the.. |
| 17.10.2023 | 22:15 | EDGAR2 | Form S-1/A - General form for registration of securities.. |
| 11.10.2023 | 13:05 | GLOBE | ZyVersa Therapeutics Announces Peer-Reviewed Publication in.. |
| 04.10.2023 | 13:05 | GLOBE | ZyVersa Therapeutics Announces New Peer-Reviewed Publication.. |
| 27.9.2023 | 13:07 | GLOBE | ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate.. |
| 22.9.2023 | 12:35 | GLOBE | ZyVersa Therapeutics Announces Research Published in The.. |
| 20.9.2023 | 23:15 | EDGAR2 | Form 8-K/A - Current report: [Amend] |
| 14.9.2023 | 13:00 | EDGAR2 | Form 8-K - Current report |
| 13.9.2023 | 22:57 | EDGAR2 | Form DEFA14A - Additional definitive proxy soliciting.. |
| 13.9.2023 | 22:40 | EDGAR2 | Form DEF 14A - Other definitive proxy statements |
Hot Features
Premium
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
